Melatonin inhibits FAK signaling to suppress PD-L1 expression and enhance chemosensitivity in triple-negative breast cancer.
Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targetable hormone receptors, making conventional chemotherapy the primary treatment option, despite its associated toxicity and potential for drug resistance. Melatonin, a natural hormone with anticancer and immunomodulatory properties, has shown promise in multiple cancers; however, its role in TNBC remains unclear.
We analyzed serum melatonin levels in TNBC patients and healthy controls. The biological effects of melatonin were then evaluated in human (MDA-MB-231, MDA-MB-468) and murine (4T1) TNBC cell lines. In vitro assays assessed proliferation, apoptosis, migration, epithelial-mesenchymal transition (EMT), and chemosensitization. Mechanistic pathways were analyzed, and an orthotopic 4T1 syngeneic mouse model was employed to confirm antitumor and immunomodulatory effects in vivo.
We found that TNBC patients had significantly lower serum melatonin levels than healthy controls. In vitro, melatonin reduced cell viability, migration, and tumorsphere formation, and promoted apoptosis. Mechanistically, it downregulated focal adhesion kinase (FAK) and programmed death-ligand 1 (PD-L1). FAK inhibition increased melatonin sensitivity, whereas FAK overexpression conferred resistance. Melatonin also enhanced cisplatin cytotoxicity. In vivo, melatonin treatment suppressed tumor growth, increased CD8⁺ T-cell infiltration, and decreased PD-L1 expression and the number of FOXP3⁺ regulatory T cells in the tumor microenvironment.
Melatonin suppresses TNBC progression by inhibiting proliferation and migration and by modulating the immune microenvironment through the FAK-PD-L1 axis. These findings highlight melatonin as a potential low-toxicity adjunct to enhance the efficacy of current TNBC therapies.
We analyzed serum melatonin levels in TNBC patients and healthy controls. The biological effects of melatonin were then evaluated in human (MDA-MB-231, MDA-MB-468) and murine (4T1) TNBC cell lines. In vitro assays assessed proliferation, apoptosis, migration, epithelial-mesenchymal transition (EMT), and chemosensitization. Mechanistic pathways were analyzed, and an orthotopic 4T1 syngeneic mouse model was employed to confirm antitumor and immunomodulatory effects in vivo.
We found that TNBC patients had significantly lower serum melatonin levels than healthy controls. In vitro, melatonin reduced cell viability, migration, and tumorsphere formation, and promoted apoptosis. Mechanistically, it downregulated focal adhesion kinase (FAK) and programmed death-ligand 1 (PD-L1). FAK inhibition increased melatonin sensitivity, whereas FAK overexpression conferred resistance. Melatonin also enhanced cisplatin cytotoxicity. In vivo, melatonin treatment suppressed tumor growth, increased CD8⁺ T-cell infiltration, and decreased PD-L1 expression and the number of FOXP3⁺ regulatory T cells in the tumor microenvironment.
Melatonin suppresses TNBC progression by inhibiting proliferation and migration and by modulating the immune microenvironment through the FAK-PD-L1 axis. These findings highlight melatonin as a potential low-toxicity adjunct to enhance the efficacy of current TNBC therapies.
Authors
Wu Wu, Yang Yang, Chang Chang, Pan Pan, Li Li, Wu Wu, Kan Kan, Chen Chen, Hou Hou, Luo Luo
View on Pubmed